Yifan Pharmaceutical Co (SZSE:002019) Total Liabilities : ¥3,950 Mil (As of Sep. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Yifan Pharmaceutical Co Total Liabilities?

Yifan Pharmaceutical Co's Total Liabilities for the quarter that ended in Sep. 2024 was ¥3,950 Mil.

Yifan Pharmaceutical Co's quarterly Total Liabilities increased from Mar. 2024 (¥3,431.96 Mil) to Jun. 2024 (¥3,693.34 Mil) and increased from Jun. 2024 (¥3,693.34 Mil) to Sep. 2024 (¥3,950.41 Mil).

Yifan Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 (¥3,390.64 Mil) to Dec. 2022 (¥3,397.39 Mil) but then declined from Dec. 2022 (¥3,397.39 Mil) to Dec. 2023 (¥3,244.68 Mil).

Yifan Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Yifan Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yifan Pharmaceutical Co Total Liabilities Chart

Yifan Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3,244.09

2,988.94

3,390.64

3,397.39

3,244.68

Yifan Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															3,080.64	3,244.68	3,431.96	3,693.34	3,950.41

Yifan Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Yifan Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2187.362	+	(878.772	+	178.545
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3,245

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	11499.586	-	8254.907
	=	3,245

Yifan Pharmaceutical Co's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2983.757	+	(756.202	+	210.447
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3,950

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	12369.759	-	8419.353
	=	3,950

Yifan Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Yifan Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Yifan Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yifan Pharmaceutical Co Ltd (SZSE:002019) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 50 Qinshan, Jincheng, Lin'an Economic Development Zone, Hangzhou, Zhejiang, CHN, 311300

Website

https://en.yifanyy.com

Yifan Pharmaceutical Co Ltd is a China-based company engaged in R&D and production company focusing on the pharmaceutical and health sectors. Its vision is to develop drugs with definite clinical values, to help disease-afflicted patients regain health. The group focuses on four business areas such as biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs). The products of the company are Ryzneuta, Plerixafor Injection, Vincristine Sulfate, Skin Allergy Reli, and Others.

Executives

Ye Yi Qun	Director
Zhang Da Wei	Executives
Geng Yu Hong	Executives
Feng De Qi	Directors, Directors, and Executives
Zhou Ben Yu	Director
Lin Xing	Directors, executives
Yu Hai Xia	Executives
Cheng Xian Feng	Directors, executives
Xu Guo Han	Supervisors
Cao Shi Mei	Director
Lin Guan Yu	Director
Zhang Lian Chun	Executives
Guo Xin Fu	Director
Zheng Shi Ming	Supervisors
Yin Hang Hua	Executives

Yifan Pharmaceutical Co Headlines

No Headlines